Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced new preclinical ...
Results strongly support continued development of Cytoki's oral IL-22 program for UC which is part of its growing preclinical pipeline of IL-22-based assets SØBORG, Denmark, May 8, 2025 /PRNewswire/ - ...
Ampersand Biomedicines presents preclinical data on AMP-220, a gut-targeted IL-22 AND-Body therapeutic, at AAI 2026: Boston Tuesday, April 21, 2026, 17:00 Hrs [IST] Ampersand Biom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results